← Vanda Pharmaceuticals Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $146.0m |
$165.1m
+13.06%
|
$193.1m
+16.98%
|
$227.2m
+17.64%
|
$248.2m
+9.23%
|
$268.7m
+8.27%
|
$254.4m
-5.32%
|
$192.6m
-24.27%
|
$198.8m
+3.18%
|
$216.1m
+8.72%
|
$215.7m
-0.18%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | $64.8m |
$58.1m
-10.27%
|
$20.5m
-64.73%
|
$24.5m
+19.41%
|
$23.4m
-4.59%
|
$25.6m
+9.69%
|
$24.3m
-5.26%
|
$14.8m
-39.07%
|
$11.3m
-23.53%
|
$13.0m
+15.29%
|
$13.5m
+3.54%
|
|
| Gross Profit (derived) | $81.2m |
$106.9m
+31.67%
|
$172.6m
+61.41%
|
$202.7m
+17.43%
|
$224.8m
+10.90%
|
$243.1m
+8.12%
|
$230.1m
-5.33%
|
$177.8m
-22.71%
|
$187.5m
+5.41%
|
$203.1m
+8.32%
|
$202.2m
-0.42%
|
|
| Research and Development Expense | $29.2m | $38.5m | $43.6m | $48.6m | $55.6m | $75.4m | $85.8m | $76.8m | $74.4m | $109.3m | $117.0m | |
| Selling, General and Administrative Expense | $99.8m | $123.8m | $105.8m | $129.7m | $140.5m | $124.0m | $136.5m | $112.9m | $146.4m | $238.0m | $263.4m | |
| Amortization of Intangible Assets | $10.9m | $1.8m | $1.5m | $1.5m | $1.5m | $1.5m | $1.5m | $2.1m | $7.3m | $7.0m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | ($18.6m) |
($16.9m)
+8.98%
|
$21.7m
+228.60%
|
$22.8m
+4.93%
|
$27.2m
+19.42%
|
$42.2m
+54.80%
|
$6.3m
-84.99%
|
($14.0m)
-320.45%
|
($40.7m)
-191.43%
|
($151.2m)
-271.79%
|
($185.7m)
-22.82%
|
|
| Other Income | $665k | $1.5m | $3.6m | $6.2m | $4.4m | $199k | $5.0m | $20.3m | $17.7m | $12.5m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($18.1m) | ($15.7m) | $25.1m | $28.8m | $31.7m | $42.2m | $11.2m | $6.2m | ($23.0m) | ($138.9m) | ($177.2m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $42.4m | $11.3m | $6.3m | ($22.9m) | ($138.6m) | ($177.2m) | |
| Income Tax Expense (Benefit) | $104k | $136k | $138k | ($86.5m) | $8.3m | $9.2m | $5.0m | $3.8m | ($4.0m) | $81.8m | $97.7m | |
| Net Income (Loss) Attributable to Parent | ($18.0m) |
($15.6m)
+13.56%
|
$25.2m
+261.93%
|
$115.6m
+358.40%
|
$23.3m
-79.80%
|
$33.2m
+42.06%
|
$6.3m
-81.07%
|
$2.5m
-60.02%
|
($18.9m)
-853.29%
|
($220.5m)
-1066.53%
|
($274.9m)
-24.66%
|
|
| Earnings Per Share, Basic | ($0.41) | ($0.35) | $0.50 | $2.17 | $0.43 | $0.60 | $0.11 | $0.04 | ($0.33) | ($3.74) | ($4.64) | |
| Earnings Per Share, Diluted | ($0.41) | ($0.35) | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | ($0.33) | ($3.74) | ($4.64) | |
| Weighted Average Number of Shares Outstanding, Basic | 43.4m | 44.7m | 50.9m | 53.1m | 54.4m | 55.5m | 56.5m | 57.4m | 58.1m | 58.9m | 59.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 43.4m | 44.7m | 53.0m | 54.8m | 55.2m | 56.9m | 57.0m | 57.6m | 58.1m | 58.9m | 59.5m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $164.6m | $182.0m | $171.4m | $204.4m | $220.9m | $226.5m | $248.1m | $206.6m | $239.4m | $367.3m | — |